Gene sequence construct for gene therapy of human immunodeficiency virus infection
US-2024352096-A1 · Oct 24, 2024 · US
US10113193B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10113193-B2 |
| Application number | US-201615086736-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 31, 2016 |
| Priority date | Mar 31, 2015 |
| Publication date | Oct 30, 2018 |
| Grant date | Oct 30, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Methods are provided to improve the expression of protein complexes by tuning the expression levels of each component required for the assembly of the complex. These methods are effective in limiting the expression of the dominant chain and, thus, equilibrating their relative abundance. The methods provided herein lead to a significant increase in productivity and final bispecific yields both in transient expression systems as well as in stably transfected mammalian cells.
Opening claim text (preview).
What is claimed is: 1. A method to increase production yield of a protein complex that comprises more than one polypeptide, the method comprising: (a) providing more than one nucleic acid molecules encoding the polypeptides in the protein complex, wherein the protein complex is a multispecific antibody or a bispecific antibody; (b) introducing the nucleic acid molecule(s) into a cell; (c) culturing the cell under conditions that allow for the expression of polypeptides in the protein complex; and (d) decreasing expression of at least one of the polypeptides in the protein complex by modifying transcription rate, by modifying translation rate, by modifying mRNA stability, by modifying mRNA secondary structure, or by modifying any combination of these factors, wherein the production yield of the protein complex is increased compared to when the expression of at least one of the polypeptides is not decreased. 2. The method of claim 1 , wherein the reduction in expression of one of the polypeptides in the protein complex is achieved by modifying transcription rate, translation rate, or mRNA stability. 3. The method of claim 1 , wherein the reduction in expression of one of the polypeptides in the protein complex is achieved by modifying mRNA secondary structure. 4. The method of claim 1 , wherein the reduction in expression of one of the polypeptides in the protein complex is achieved by modifying translation rate, by altering the codon composition of that polypeptide. 5. The method of claim 4 , wherein the reduction in expression of one of the polypeptides in the protein complex is achieved by modifying translation rate, by altering the codon composition of that polypeptide via the replacement of certain codons with codons that are less frequently used in the host cell that is used for expression of the protein complex. 6. The method of claim 5 , wherein the reduction in expression of one of the polypeptides in the protein complex is achieved by modifying translation rate, by altering the codon composition of that polypeptide via the replacement of certain codons with codons that are less frequently used in a mammalian host cell used for expression of the protein complex. 7. The method of claim 1 , wherein the protein complex is a multispecific antibody. 8. The method of claim 1 , wherein the protein complex is a bispecific antibody. 9. The method of claim 8 , wherein the bispecific antibody is composed of two different light chains and a common heavy chain. 10. The method of claim 1 , wherein more than one protein complex is co-expressed. 11. The method of claim 10 , wherein the protein complexes are antibodies, and wherein more than one antibody is co-expressed.
Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title
General methods for enhancing the expression · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title
for animal cells · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.